Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  -15.00 -3.19% 455.00 36,139 09:21:45
Bid Price Offer Price High Price Low Price Open Price
440.00 470.00 465.00 455.00 460.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -11.21 -26.23 197
Last Trade Time Trade Type Trade Size Trade Price Currency
17:34:59 O 98 439.978 GBX

Faron Pharmaceuticals Oy (FARN) Latest News

More Faron Pharmaceuticals Oy News
Faron Pharmaceuticals Oy Takeover Rumours

Faron Pharmaceuticals Oy (FARN) Discussions and Chat

Faron Pharmaceuticals Oy Forums and Chat

Date Time Title Posts
28/3/202016:01Respite for ARDS sufferers1,472

Add a New Thread

Faron Pharmaceuticals Oy (FARN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Faron Pharmaceuticals Oy trades in real-time

Faron Pharmaceuticals Oy (FARN) Top Chat Posts

DateSubject
28/3/2020
08:20
Faron Pharmaceuticals Oy Daily Update: Faron Pharmaceuticals Oy is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FARN. The last closing price for Faron Pharmaceuticals Oy was 470p.
Faron Pharmaceuticals Oy has a 4 week average price of 235p and a 12 week average price of 206p.
The 1 year high share price is 494p while the 1 year low share price is currently 54p.
There are currently 43,290,747 shares in issue and the average daily traded volume is 344,372 shares. The market capitalisation of Faron Pharmaceuticals Oy is £196,972,898.85.
20/2/2020
11:59
bioking: DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY Diurnal (DNL) Market Cap £27 M Price: 31p Upcoming Catalysts: MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 2Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses
23/5/2019
14:27
mister md: so when it rallied to 80p early this month they said "TURKU - FINLAND, 2 May 2019 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical company, notes the recent movement in its share price and the Company confirms that it knows of no operational or corporate reason for the share price move." So why are people buying at 100p + ?
09/11/2018
14:58
spmc: For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10.
22/6/2018
13:13
craigo121: You could argue Director(non exec) buying 48k better than selling his quite considerable stash!! OVER 1 MILLION# Bet he wishes sold few months ago!! The 50k buy looks to me like a desperate attempt into showing confidence in an already depleted share price.
18/6/2018
18:21
ic0gcds00: It hurts to see the share price plummet so much after an £8 placingThe board need to man up and come up with some positves for dhareholders
13/6/2018
18:19
alamaison5: The cash? Just did a placing...and at a much higher price than the share price is now... Imagine the face of the investors when the price crashed. Shouldn't they average down, lol...
04/6/2018
10:26
kirk 6: I did see that share price should be north of £8 now
15/5/2018
10:45
craigo121: 90% drop in share price does not make a bargain! It's dropped 90% for a reason the drug failed they spent 30 million developing not much left in the coffers apart from the 2nd drug 5 million development should equate to 50-60p per share
10/5/2018
15:16
bangers and cash1: Placebo makers, don’t know who to trust some random guy with a short or institutions who decided to buy at many multiples of the share price. Hmmm. Also how can you claim people are ramping when you are flat out lying and posting over and over again, clearly trying to scare people into selling to suit your short. Please leave.
09/5/2018
20:45
deltalo: The bounce has happened but like a bouncing ball the heigh's get lower with each bounce. There is no income to pay for any new trials let alone pay for the rest of the last one. The whole inflation in the share price was on the back of a positive outcome from this trial from the start. What I would like to know is where's the funding coming from and if there is any new trials, how much and how many years will it take. I know something and that's I'm not waiting and I'm not paying. This will fall to its real worth.
Faron Pharmaceuticals Oy share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
FARN
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200329 06:19:33